http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 29 Jul 2026 07:42:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Business+Wire/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Business+Wire/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Business+Wire/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Business+Wire/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Business+Wire/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Business+Wire/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Business+Wire/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Business+Wire/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Business+Wire/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Business+Wire/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Business+Wire/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Business+Wire/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Business+Wire/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Business+Wire/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Business+Wire/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Business+Wire/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Business+Wire/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Business+Wire/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Business+Wire/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Business+Wire/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Business+Wire/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Business+Wire/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Business+Wire/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Business+Wire/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA